NovaGo Logo

Board of Directors

Professor Martin E. Schwab, PhD, hon. MD
President of the Board

Martin E. Schwab is a founder and President of NovaGo. He is a key opinion leader in the field of spinal cord and brain injury and repair, and holds faculty positions at both the University of Zurich and ETH Zurich, Switzerland. He discovered the existence of “inhibitors of neurite growth” as a cause of the absent regeneration of injured fiber tracts in the central nervous system. An important breakthrough, honored by numerous international prizes, was the demonstration that blocking of the most potent of those nerve fiber growth inhibitors, Nogo-A, led to regeneration and functional repair in adult rats and monkeys after spinal cord injury. These results overthrew the dogma that the adult mammalian central nervous system would be unable to regenerate.

Professor Roger M. Nitsch, MD
Member of the Board

Roger M. Nitsch co-founded NovaGo and is a member of the Board of Directors. A neuroscientist with a background in medicine, he is recognized as a key opinion leader in neurodegenerative disease research, and as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner and Member of the German Academy of Sciences directs the Institute for Regenerative Medicine (IREM) at the University of Zurich, Switzerland, and is a co-founder and President of Neurimmune Holding AG.

Jan Grimm, PhD
Member of the Board

Jan Grimm is a neuroscientist with 15 years of experience in US and European biotech focusing on the development of antibody-based therapeutics. Dr. Grimm is the CSO and a board member of Neurimmune Holding AG which he co-founded in 2006. Before joining Neurimmune, he led the Alzheimer’s disease research efforts at Rinat Neuroscience in San Francisco that was acquired by Pfizer in 2006. During his tenure at Neurimmune and Rinat, multiple antibody drug candidates for the treatment of Alzheimer’s disease, Parkinson’s disease, Tauopathies and amyotrophic lateral sclerosis advanced from discovery to preclinical and clinical development.

Dominik Escher, PhD 
Member of the Board

Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody fragment drugs. Alcon acquired ESBATech for USD 589 million in 2009. Subsequently until 2016 Vice President of Alcon Research & Development and at Novartis Member of the Global Ophthalmology Leadership and Global Biologics Leadership. Since 2002, on the Board of the Swiss Biotech Association and President since 2013. PhD Molecular Biologist.